Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

ClinicalTrials.gov ID: NCT06679582

Public ClinicalTrials.gov record NCT06679582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

Study identification

NCT ID
NCT06679582
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Sutro Biopharma, Inc.
Industry
Enrollment
24 participants

Conditions and interventions

Interventions

  • Luveltamab tazevibulin Drug

Drug

Eligibility (public fields only)

Age range
1 Day to 12 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 3, 2024
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update posted
Aug 23, 2025

2024 – 2025

United States locations

U.S. sites
23
U.S. states
18
U.S. cities
22
Facility City State ZIP Site status
Childrens Hospital of Alabama Birmingham Alabama 35233
Childrens Hospital of Los Angeles Los Angeles California 90027
Lucile Packard Childrens Hospital-Stanford Palo Alto California 94304
Children's Hospital of Colorado Aurora Colorado 80045
Childrens National Hospital Washington D.C. District of Columbia 20010
Children's Hospital of Atlanta-Emory Atlanta Georgia 30322
Ann & Robert H. Lurie Childrens Hospital Chicago Illinois 60611
Dana-Farber Cancer Institute Boston Massachusetts 02215
University of Minnesota-Masonic Cancer Center Minneapolis Minnesota 55455
Children's Mercy Hospital Kansas City Missouri 64108
Washington University-School of Medicine St Louis Missouri 63110
Columbia University Irving Medical Center New York New York 10032
Duke University Medical Center Durham North Carolina 27711
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Nationwide Children's Hospital Columbus Ohio 43205
Oregon Health & Science University Portland Oregon 97239
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
St. Jude Children's Research Hospital Memphis Tennessee 38105
Cook Children's Medical Center Fort Worth Texas 76104
Baylor College of Medicine-Dan Duncan Comprehensive Cancer Center Houston Texas 77030
MD Anderson Cancer Center Houston Texas 77030
Massey Cancer Center-Adult Outpatient Pavillion Richmond Virginia 23219
Seattle Childrens Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06679582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 23, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06679582 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →